Interview of the President, Mr. Katsika Marios, to the Hellenic Society of Pharmaceutical Management.
Marios Katsikas: FARAN continues to be one of the fastest growing companies in the industry The Greek pharmaceutical company FARAN is one of the fastest growing companies in the sector. With a model that combines our own branded generics and important original products from international firms, we continue our upward course, as in recent years […]
FARAN S.A. & STADA Arzneimittel AG collaboration announcement FARAN S.A. and STADA Arzneimittel AG are pleased to announce the launch of their collaboration in the field of Osteoporosis. More specifically, FARAN undertakes the promotion and distribution in the Greek market of the STADA Arzneimittel AG product MOVYMIA, the first Biosimilar Teriparatide of STADA Arzneimittel AG.
Faran’s team participated at the Greek “Race for the Cure”, wanting to highlight the value of participation, the team took part in the 2 km walk. An event focusing on the prevention of health and the promotion of the women’s strength who have experienced the disease. FARAN is aware of social matters and especially to […]
Faran SA supports the needs of the Oncology Community for ongoing scientific training and publication of high-level scientific work, by donating the prize of the two thousand Euros (2,000€) at the Hellenic Society of Medical Oncologists (HSMO) on an annual basis. The award is given to the best published work at FCO journal (Forum of […]
Faran S.A. aims to raise awareness on Kidney cancer, by carrying out sport-social event with the quote “Score a Goal for patients with Kidney Cancer”. On World Kidney Cancer Day Faran’s team devote the day on sport activities. The action was organized, coordinated and implemented by the Department of Oncology, strengthening the social profile of […]
FARAN SA and SANDOZ member of the Novartis Group, after their successful collaboration, are pleased to announce the expansion of their cooperation, undertaking the promotion and distribution of another product with the active substance Epoetin alpha.
FARAN SA and NOVARTIS (Hellas) SA are pleased to announce the launch of their collaboration in the field of therapeutic oncology. More specifically, FARAN undertakes the promotion and distribution in the Greek market of the NOVARTIS products TYVERB (Lapatinib) and ZYKADIA (Ceritinib). TYVERB (Lapatinib) is indicated for the treatment of patients with metastatic breast cancer […]
Faran SA, one of the historical Pharmaceutical companies with a presence of more than 70 years in the Greek Pharmaceutical market, received the “2018 Pharmaceutical Sector Business Award” from the Internal Medicine Society of Greece, as an acknowledgement of the continuous contribution of Faran to the Healthcare sector and the public health.